LifeScan Inc., Malvern, PA, USA.
LifeScan Scotland Ltd., Inverness, UK.
J Diabetes Sci Technol. 2020 Sep;14(5):912-916. doi: 10.1177/1932296820906184. Epub 2020 Feb 14.
The OneTouch Verio Reflect blood glucose monitor (BGM) has market clearance in several countries based in part on fulfilling the lay user and system accuracy criteria described in ISO15197:2015. However, the Food and Drug Administration (FDA) does not recognize the accuracy criteria in ISO15197 as a basis for gaining regulatory clearance for these devices. The current study evaluates the BGM using the accuracy guidelines issued by the agency for self-monitoring blood glucose test systems for over-the-counter use. Glucose results were accurate vs comparator over a wide glucose range and met lay user and glucose accuracy criteria at extreme glucose values as described in the FDA guidance..
OneTouch Verio Reflect 血糖仪(BGM)已在多个国家获得市场准入,部分基于满足 ISO15197:2015 中描述的非专业用户和系统准确性标准。然而,食品和药物管理局(FDA)并不认可 ISO15197 中的准确性标准作为这些设备获得监管批准的依据。本研究使用 FDA 发布的用于非处方使用的自我监测血糖测试系统的准确性指南来评估 BGM。在广泛的血糖范围内,血糖仪的血糖检测结果与对照相比是准确的,并且在 FDA 指南中描述的极端血糖值下满足非专业用户和血糖准确性标准。